We previously reported that due to the inherent variability of SHBG, clinical hypogonadism is over/under-diagnosed in 20% of patients. We further analyzed the data between classically hypogonadal men (G1 -total testosterone (TT) < 300) and those men who were "missed" but were hypogonadal using calculated bioavailable testosterone (cBT < 210) with the use of SHBG (G2). We analyzed the role of SHBG in the routine testing of male factor infertility by analyzing the relationship of TT and BT to common infertility parameters.
INTRODUCTION AND OBJECTIVES:
We previously reported that due to the inherent variability of SHBG, clinical hypogonadism is over/under-diagnosed in 20% of patients. We further analyzed the data between classically hypogonadal men (G1 -total testosterone (TT) < 300) and those men who were "missed" but were hypogonadal using calculated bioavailable testosterone (cBT < 210) with the use of SHBG (G2). We analyzed the role of SHBG in the routine testing of male factor infertility by analyzing the relationship of TT and BT to common infertility parameters.
METHODS: Retrospective review of 168 males seen in a fertility clinic from 2012-2014, to investigate the accuracy of TT in the biochemical diagnosis of hypogonadism using cBT as the reference value. The relationship between TT and other infertility parameters were calculated using nonparametric Spearman correlations. We compared semen parameters between G1 and G2 in men with and without azoospermia. We utilized a multivariable sub-analysis with linear regression with backward elimination of non-significant variables. The possible predictors in the model included age, TT, varicocele, FSH, and SHBG.
RESULTS: Using Spearman correlations, SHBG independently predicted lower semen parameters by a similar magnitude as FSH for sperm concentration (r¼ -0.24, p ¼ 0.0027) and motility (r¼ -.16, p¼.0447). Semen parameters were available for 76 men who met criteria for G1 and 46 for G2. Only SHBG levels differed significantly upon initial group comparision (p¼.0001). After excluding men with azoospermia, G1 had 62 and G2 had 45 men respectively. SHBG remained significant (P¼.0001) and sperm motility (p ¼ .057) and sperm concentration (p¼.09) approached significance. Using a more stringent cutoff for G2 (T<156) sperm motility was significantly different in G1 and G2 (p¼.014). Linear regression to predict sperm motility and concentration eliminated age, TT, and varicocele from the model e leaving just FSH and SHBG. When predicting sperm motility, SHBG was no longer statistically significant (p¼.0973) when FSH (p¼0.0231) was in the model. For sperm concentration, SHBG was significant (p¼0.0186) when FSH (p¼0.0079) was in the model. CONCLUSIONS: Our data demonstrates the utility of SHBG in the initial hormonal evaluation of males seen in a fertility clinic. The addition of SHBG to TT serum testing facilitates more accurate diagnosis with FT and cBT, as SHBG was the only significant parameter able to distinguish between true hypogonadal and eugonadal patients. In addition, elevated SHBG levels independently predicted decreased sperm motility and sperm concentration.
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MP35-04 EFFECT OF MEDICAL COMORBIDITIES AND THEIR TREATMENT ON SPERMATOGENESIS IN MALE INFERTILITY PATIENTS
Koji Shiraishi*, Shintaro Oka, Hideyasu Matsuyama, Ube, Japan INTRODUCTION AND OBJECTIVES: A close relationship has been shown between male infertility and general health status. The aims of this study were to investigate the prevalence and effect of medical comorbidities on spermatogenesis in Japanese men and to determine whether the treatment of medical comorbidities is effective for improving semen parameters.
METHODS: Under the approval of the institutional ethics committee, a retrospective chart review was performed for 5,337 men with a mean age of 35 years who were consecutively examined due to male infertility between April 2007 and September 2016. The initial evaluations were comprised of a history, a physical examination, at least two semen analyses, and endocrinology examinations in the morning. Further blood tests were ordered when surgery was indicated. Hormonal and spermatogenic parameters were compared between men with and without medical comorbidities. For men who were diagnosed with medical comorbidities during the infertility evaluation, the semen parameters were compared between those who did and did not undergo treatment of the comorbidities.
RESULTS: Significant medical comorbidities were found in 525 of 5,337 (9.8%) men, including 1.9% with mental (e.g., depression), 1.8% with circulatory (e.g., hypertension), 1.7% with skin (e.g., atopic dermatitis), 1.3% with kidney, 1.2% with respiratory diseases, 1.2% with diabetes, 1.0% with hyperuric acid and 0.9% with dyslipidemia. Fifty-three men (1%) exhibited a Charlson comorbidity index of more than 1 point. Testicular size (p<0.05), semen volume (p<0.01), sperm concentration and motility (p<0.001) and serum testosterone were significantly lower, and FSH was significantly higher (p<0.01) in men with comorbidities than in men without comorbidities. Of the 115 (2.2%) men who were diagnosed with comorbidities during the infertility evaluation (mainly hypertension, diabetes, hyperuric acid, and dyslipidemia) and underwent no specific infertility treatment (e.g., varicocelectomy, hormonal therapy), significant improvements in sperm concentration and motility were observed after six months of follow-up in men who underwent immediate treatment for the medical comorbidities (n¼73) compared to men who did not receive treatment (n¼42) (p<0.05).
CONCLUSIONS: Medical comorbidities are associated with the impairment of sperm production. Male infertility evaluation offers not only specific corrective therapy to improve semen parameters but also therapy for non-specific medical comorbidities, which may be beneficial for restoring general health status and spermatogenesis. . 197, No. 4S, Supplement, Saturday, May 13, 2017 
